Electric Bug – Your communications, GPS & navigation leader in SA since 1976. Trucks & 4WD our specialty, knowledge is our winning edge.
Cel-Fi devices are essential for boosting mobile signals, both indoors and outdoors. If you are on the move and heading into an area where you suspect that there’s low mobile signal strength, or if you live in a region where your carrier’s mobile signal is poor, you can depend on these mobile phone boosters to boost both voice quality and data speeds.
Electric Bug is a family-run electronic goods store that aims to provide superior product knowledge, exceptional customer services and innovative solutions when buying your cel-fi devices. Our online store has a variety of communication and navigation products that we supply to over 700 businesses.
Some of the products you can buy from us include cellular boosters, RAM mounts, satellite communication, dashcams, UHF handheld, UHF CB radios, Geocaching, among other products. We also offer various services, including repairs, warranty repairs, vehicle installation and equipment hire.
We have a wide range of cel-fi products from reputable brands. Each of our mobile phone boosters come with numerous benefits, including:
- Easy installation process
- Matched antenna
- They provide multi-user mobile coverage
- They are network safe
- Boost 4G or boost 5G signal
- Provide up to 70dB system gain
- It doesn’t interfere with other wireless devices
- Ideal for trucks, RVs, vehicles and boats
- They are rated as weather-resistant
Feel free to talk to our team of experts to find out more about our products and services. Our team cannot wait to hear from you.
It comes with Website and Mobile Applications.
Our Cel Cab Booking Clone Script is one of the latest clone scripts which is a multi-vendor Cab Booking Clone Script.
Our online taxi booking system will assist you to improve your customer service and manage your taxi transfer business more efficiently.
You can add as many cabs and extras as you'll offer.
The taxi script provides an easy, step-by-step booking process and an intuitive backend administration with password-secured access.
Add a sensible Cel Cab Booking Software on your cab Booking website and make online bookings and payments possible!
ASCO: axi-cel in ZUMA-1Abstract No : 8012Abstract Type : Oral Abstract SessionIndication : Diffused Large B-Cell Lymphoma (DLBCL)Intervention : YescartaCompany : Kite, a Gilead CompanyTechnology : CAR T Cell TherapyBased on this limited sample size, reTx with axi-cel may have clinical efficacy, although transient, in some pts, especially those who achieve CR with 1st Tx.
CAR T cell expansion and severe CRS and NEs may be attenuated at reTx.
Further studies with additional pts are needed to confirm these results.View More: https://www.delveinsight.com/asco-conference/article/zuma-1 GSK: Cell Therapy and Next-generation Immuno-oncologyAt this year’s ASCO meeting, they will showcase presentations on investigational therapies, including belantamab mafodotin, an antibody-drug conjugate for multiple myeloma, and GSK3359609, an inducible T-cell co-stimulator (ICOS) agonist for patients with head and neck cancer.View More: https://www.delveinsight.com/asco-conference/article/gsk-cell-therapy-next-generation-immuno-oncology IMbrave150 TRIAL of AtezolizumabAtezo + Bev HCCIMbrave150 demonstrated statistically significant and clinically meaningful improvement in both OS and PFS with atezo + bev vs sor in pts with unresectable HCC who have not received prior systemic therapy.
Pts achieved CRs regardless of poor prognostic factors or etiology.
Atezo + bev may be a practice-changing treatment for pts with unresectable HCC.View More: https://www.delveinsight.com/asco-conference/article/imbrave150 ASCO: KEYNOTE-204Abstract No : 8005Abstract Type : Oral Abstract SessionIndication : Hodgkin’s Lymphoma (HL)Intervention : PembrolizumabCompany : Merck Sharp & Dohme Corp., a subsidiary of Merck & Co.Technology : ImmunocheckpointIn pts with R/R cHL, pembro was superior to BV and demonstrated statistically significant and clinically meaningful improvement in PFS across all subgroups, with safety consistent with previous reports.
Pembro monotherapy should be standard of care for this pt population with R/R/cHL.View More: https://www.delveinsight.com/asco-conference/article/NCT02684292 ASCO: INO-5401 + INO-9012 with CemiplimabAbstract No : 2514Abstract Type : Oral Abstract SessionIndication : Glioblastoma MultiformeIntervention : INO-5401 and INO-9012 + CemiplimabCompany : Inovio PharmaTechnology : T cell therapy/Monoclonal AntibodyINO-5401 + INO-9012 in combination with cemiplimab and RT/TMZ has an acceptable safety profile, is immunogenic and may show a survival advantage in patients with newly-diagnosed GBM.View Report: https://www.delveinsight.com/asco-conference/article/NCT03491683
